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The human type I IFN gene family consists of 13 genes
encoding IFN-
 
 
 
 subtypes and one gene each for IFN-
 
 
 
and -
 
 
 
. The type I IFN proteins show similarities with re-
spect to both structure and function; for instance, they are
typically produced by cells exposed to virus and interact
with the same receptor, the IFNAR (1). The type I IFNs
have well established direct antiviral and antiproliferative
effects, but also several prominent immunoregulatory ac-
tions that have come into focus in recent years (1–3). The
latter include the ability to promote survival and differenti-
ation of antigen-activated Th1 cells. These effects of type I
IFN may, in part, be due to their ability to activate signal
transducer and activator of transcription (STAT)4 and
maintain expression of a functional IL-12R. Type I IFN
can also cause maturation of efficiently antigen-presenting
monocyte-derived dendritic cells (DCs) and stimulate B
lymphocytes (4, 5).
 
The IFN-
 
 
 
–producing Cells.
 
While many cell types pro-
duce type I IFN in vitro when exposed to double-stranded
(ds)RNA and some RNA viruses, a specialized leukocyte is
responsible for the IFN-
 
 
 
 production induced by a wider
spectrum of agents, including viruses, bacteria, protozoa,
certain cell lines, and also unmethylated CpG-DNA (6–8).
This major IFN-
 
 
 
–producing cell (IPC) was early on des-
ignated natural IPC (NIPC) and subsequent work (for a re-
view see reference 6) revealed that NIPCs were infrequent
(
 
 
 
0.1% of PBMCs) but very productive on a per cell basis
(
 
 
 
10 pg IFN-
 
 
 
 per cell). The expression of the IFN-
 
 
 
/
 
 
 
genes induced in NIPCs was markedly dependent on co-
stimulation (“priming”) of the cells by cytokines, in partic-
ular IL-3, GM-CSF, and type I IFNs. These cells lacked
lineage specific surface antigens, but expressed MHC class
II (for a review, see reference 6). The NIPCs were shown
to express, e.g., CD4, CD36, CD40, CD44, CD45RA,
and CD83, but lacked CD80, CD86, and CD11c, suggest-
ing they were immature DCs (9). Their phenotype was in
fact similar to a subsequently identified DC precursor (10,
11), now often referred to as plasmacytoid DCs (PDCs).
Such purified PDCs were also shown to contain the NIPC
population (12, 13). While mature PDCs were originally
shown to induce Th2 cell development, they can effi-
ciently promote Th1 immune responses in vitro to antigens
associated with type I IFN induction (14, 15). The latter
may occur especially in viral infections, but because the
NIPCs/PDCs express toll-like receptor 9 (TLR9) that rec-
ognizes bacterial unmethylated CpG-DNA (16, 17), they
could also be important in bacterial infections. In fact, si-
multaneous ligation of CD40 on NIPCs/PDCs and activa-
tion by CpG-DNA induce the production of high levels of
both IFN-
 
 
 
 and IL-12 (16), both cytokines important in
Th1 immune responses.
The lack of specific markers directly identifying NIPCs/
PDCs, have hampered the studies of these cells. A great
step forward was the demonstration of two novel markers,
BDCA-2 and BDCA-4, present on 
 
 
 
0.4% of PBMCs
(18). These antigens seem to be unique for PDCs in periph-
eral blood, although BDCA-2 is lost as the cells mature and
BDCA-4 also appears on differentiating monocyte-derived
and CD34
 
 
 
 cell-derived DCs (18). In this way, for the first
time, the PDCs can be positively identified. One important
question is the identity and function of the BDCA-2 and
-4 molecules. In this issue, Dzionek and coworkers report
on the molecular cloning and characterization of BDCA-2
and show that this molecule represents a unique endocytic
type II single-CRD C-type lectin, able to target ligands
into the antigen processing and peptide-loading compart-
ment (19). Whether this is the physiological function of
BDCA-2 remains to be established, and it seems important
to identify the natural ligand(s) to this molecule. Perhaps
the most interesting finding in the paper by Dzionek et al.
is the observation that ligation of BDCA-2 inhibit the
IFN-
 
 
 
 production by NIPCs/PDCs triggered by a wide
variety of different IFN-
 
 
 
 inducers. It is intriguing that
such PDCs still can mature into efficient antigen presenters
despite downregulated IFN-
 
  
 
production (19). Therefore,
as suggested by Dzionek and coworkers, the BDCA-2
molecule and any endogenous or microbial ligands may
have an important role in immune activation by favoring
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Th2 immune responses. Another question is therefore if
BDCA-2 ligation can cause inhibition of other functions of
NIPCs/PDCs, such as IL-12 production.
 
Type I IFN and Autoimmunity.
 
One important issue is
the biological relevance of the NIPCs/PDCs and their pro-
duced cytokines in man. This is true both with regard to
the normal immune response to infectious microorganisms
and in pathological immune responses such as autoimmu-
nity. These questions are difficult to approach experimen-
tally in mice, because type I IFNs do not activate the mu-
rine Th1 pathway due to a deficiency in the activation of
STAT4 (20). Some lessons regarding the relation between
IFN-
 
 
 
 and autoimmunity can, however, be learned from
the clinic, where IFN-
 
 
 
 has been used as a therapeutic
agent for more than two decades. A prominent side effect
in IFN-
 
 
 
–treated individuals is the development of autoan-
tibodies, and as many as 19% of the patients have been re-
ported to develop an autoimmune disease (21, 22). Both
organ-specific and nonorgan-specific autoimmune diseases
have been observed. Among the latter, development of sys-
temic lupus erythematosus (SLE) during IFN-
 
 
 
 therapy
was reported already in 1990 (23). Subsequently, it was
shown that in the course of IFN-
 
 
 
 therapy of patients with
carcinoid tumors, as many as 22% develop antinuclear anti-
bodies (ANAs), 8% anti-dsDNA antibodies, and 0.7% SLE
(21, 24). These observations obviously raise the question if
not the type I IFN system could be involved in the etio-
pathogenesis of naturally occurring SLE, the prototype sys-
temic autoimmune disease that is characterized by the pres-
ence of a wide variety of autoantibodies and inflammation
in many organs and tissues.
 
Evidence for a Role of the Type I IFN System in SLE.
 
Early studies of the immune system in SLE patients re-
vealed increased serum levels of IFN, subsequently charac-
terized as IFN-
 
 
 
, that were suggested to be of importance
in the disease process (25). The serum IFN-
 
 
 
 levels in SLE
are actually sometimes as high as in patients with acute vi-
ral infections or after therapeutic injections of large IFN-
 
 
 
doses. Also, several symptoms in SLE mimic those in in-
fluenza or during IFN-
 
 
 
 therapy, for instance fever, myal-
gia, and arthralgia. Such observations were however
largely neglected by lupus immunologists. In recent years
several novel findings have been made regarding the possi-
ble mechanisms behind the ongoing IFN-
 
 
 
 production in
SLE and its cellular basis, that have renewed the interest in
the area and opened a new field in lupus research. One
first observation was that blood of SLE patients frequently
contained an inducer of IFN-
 
 
 
 production by normal
PBMCs, consisting of anti-dsDNA antibodies, and DNA in
complex (26, 27). Interestingly, this IFN-
 
 
 
–inducing fac-
tor in SLE (SLE-IIF) selectively activated the IFN-
 
 
 
 syn-
thesis in NIPCs/PDCs (27) and the same cells were also
activated in vitro by autoantibodies combined with un-
methylated CpG-containing plasmid DNA (7) or material
released by apoptotic cells (28, 29). With regard to SLE-
IIF and the combination of autoantibodies and apoptotic
cells, the Fc
 
 
 
RII (CD 32) is necessary for induction of
IFN-
 
 
 
 production, because the latter was blocked by anti-
 
Fc
 
 
 
RII antibodies and Fc-fragments or aggregated Ig,
while the F(ab)
 
 
 
2 portion of autoantibodies lost stimula-
tory activity (30; unpublished data). Furthermore, anti-
bodies against CD16 and CD64 were without effect. This
suggests that NIPCs/PDCs do express Fc
 
 
 
RII, although
their presence on the cells has not been directly demon-
strated. An in vivo role for NIPCs/PDCs in the IFN-
 
 
 
production in SLE is supported by the finding of sharply
reduced numbers of these cells in blood (26) and presence
of activated NIPCs/PDCs in the skin of SLE patients (31,
32). The noted reduction of circulating NIPCs/PDCs in
SLE patients was recently confirmed and it was also ob-
served that monocytes in SLE blood can act as antigen-
presenting cells (33). Monocyte differentiation into DCs in
vitro was achieved by SLE serum and was due to its con-
tent of IFN-
 
 
 
, underscoring the importance of this cyto-
kine in early immune activation (4) and consequently also
the autoimmune process in SLE. Finally, the activation of
the type I IFN system in SLE correlates with both disease
activity and severity (34).
 
Mechanism for the Activation and Action of the Type I IFN
System in SLE.
 
We have formulated a hypothesis that ex-
plains the activation and pivotal action of the type I IFN
system in the development of SLE (Fig. 1; see also refer-
ence 35). It is based on the initial formation of autoanti-
bodies against nucleic acid and associated proteins derived
from apoptotic cells that occur during infections because of
costimulatory effects of type I IFN and other cytokines.
This may occur regularly, but is usually self-limiting and
does not cause autoimmune disease. However, in certain
genetically predisposed individuals, immune complexes
consisting of autoantibodies and cell-derived nucleic acid–
containing material continue to activate IFN-
 
 
 
 production
as endogenous IFN-
 
 
 
 inducers, even when the infectious
microorganisms have been eliminated. The IFN-
 
 
 
 pro-
duction occurs in the NIPCs/PDCs and the prolonged
IFN-
 
 
 
 production in these cells will sustain the autoim-
mune process, resulting in generation of more autoanti-
bodies and IFN-
 
 
 
 inducers. This is facilitated by the fact
that antigen presentation and IFN-
 
 
 
 production take place
in similar if not identical DCs and that the IFN-
 
 
 
 inducers
and autoantigen are in the same molecular complex. Con-
sequently, a vicious circle is established, the activity of
which can be augmented by the recruitment of new
NIPCs/PDCs to tissues, by priming of these cells by IFN-
 
 
 
and other cytokines, by generation of more endogenous
IFN-
 
 
 
 inducers from apoptotic cells, and by formation of
more autoantibodies. Several proposed pathogenetic fac-
tors in lupus may also support such a vicious circle, such as
decreased nuclease activity, increased apoptosis in affected
tissues and decreased scavenging of apoptotic material and
immune complexes.
 
Therapeutic Targets in the Type I IFN System.
 
The pro-
posed etiopathogenic role of the type I IFN system in SLE
(Fig. 1) indicates several ways by which the IFN-
 
 
 
 produc-
tion could be inhibited by new therapeutic agents. First,
the endogenous IFN-
 
 
 
 inducers can be targeted. They can
for instance be degraded by nucleases or, alternatively, their 
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interaction with NIPCs/PDCs via, e.g., Fc
 
 
 
RII could be
inhibited. Second, the action of produced IFN-
 
 
 
 can be
prevented by the use of neutralizing anti–IFN-
 
 
 
 antibod-
ies, soluble IFNAR, or antibodies blocking the anti-
IFNAR. Third, the actual IFN-
 
 
 
–producing cells, the
NIPCs/PDCs, would be an attractive target and the IFN-
 
 
 
gene expression in the cells could be inhibited. The obser-
vation by Dzionek and coworkers (19) that ligation of
BDCA-2 with antibodies abolishes the ability of NIPCs/
PDCs to produce IFN-
 
 
 
 is in this context indeed exciting.
Such anti–BDCA-2 antibodies inhibit the response to both
a viral inducer and inducers likely to be the cause of the
IFN-
 
 
 
 production in SLE and have the significant advan-
tage of targeting the NIPCs/PDCs selectively, without af-
 
fecting their viability. The major questions here is obvi-
ously whether inhibition of the type I IFN system in SLE
patients actually is of any benefit and whether injections of
(humanized) anti–BDCA-2 antibodies have a therapeutic
effect in SLE. Obviously, this issue can only be resolved by
studies in patients and it might be wise to actually begin
with some agents closer to clinical trials, such as neutraliz-
ing anti–IFN-
 
 
 
 antibodies (36) or soluble IFNAR.
 
Inhibition of the Type I IFN System May Have Adverse Ef-
fects.
 
Before embarking on clinical trials with the objec-
tive to inhibit the type I IFN system in SLE patients, po-
tential adverse effects should be considered. Increased
susceptibility to viral infections might for instance be ex-
pected, because this is seen in mice with inactivated IF-
NAR (1). This may pose an even greater problem in SLE
patients, who already have a propensity to develop infec-
tious diseases that contribute to an increased mortality.
Consequently, the therapeutic goal in SLE must be to se-
lectively inhibit the disease-related overproduction of IFN-
 
 
 
and at the same time spare the capacity of the type I IFN
system to defeat viral infections. For this reason it is urgent
to clarify the significance of the NIPCs/PDCs in immu-
nity, especially their IFN-
 
 
 
 production. This is important,
because inhibition of the latter by for instance anti–BDCA-2
treatment could well dramatically impair the innate im-
munity to viruses in the lymphoid organs, where NIPC/
PDC-derived IFN-
 
 
 
 mainly is produced. Furthermore, if
BDCA-2 ligation of NIPCs/PDCs still allows their differ-
entiation to mature DC2, the immune system might be
skewed toward a Th2 response, resulting in for instance in-
efficient adaptive antiviral immunity and enhanced produc-
tion of autoantibodies.
In this commentary we have focused on the role of the
type I IFN system in SLE, but it may well be important
also in the development of other forms of autoimmunity.
As mentioned before, IFN-
 
 
 
 treatment of patients with
tumors or infections can induce a broad spectrum of au-
toimmune diseases, including autoimmune hepatitis, thy-
roiditis, polymyositis, thrombocytopenia, rheumatoid ar-
thritis, and insulin-dependent diabetes mellitus (IDDM;
reference 22). Besides SLE, the best characterized naturally
occurring autoimmune disease connected to type I IFN is
IDDM, where increased serum levels of IFN-
 
 
 
 and ex-
pression of IFN-
 
 
 
 in the pancreatic islets have been ob-
served (37). Furthermore, in experimental diabetes, the ex-
pression of IFN-
 
 
 
 genes in islets precedes lymphocyte
infiltration and islet cell destruction, which can be pre-
vented by neutralizing anti–IFN-
 
 
 
 antibodies (38). Ex-
pression of IFN-
 
 
 
 have also been demonstrated in joint
tissue in human rheumatoid arthritis and suggested to be of
etiopathogenic significance (2). Further studies of the con-
nection between type I IFN and human autoimmune dis-
ease are therefore highly warranted.
In conclusion, type I IFNs can contribute to loss of tol-
erance and promote an autoimmune response to several au-
toantigens, causing autoimmune reactions in many differ-
ent organs. The propensity of type I IFN to cause
autoimmunity may be related to the many immunostimu-
Figure 1. Hypothetical role of NIPCs, also termed PDCs, in SLE. The
NIPCs/PDCs become activated naturally by infectious microorganisms,
but in SLE also by DNA or RNA molecules in complex with autoanti-
bodies (endogenous IFN-  inducers) in an Fc RII-dependent manner.
Such nucleic acids, possibly bound to proteins, may be derived from apop-
totic cells. The TLR9 is expressed on the NIPCs/PDCs and mediates re-
sponses to unmethylated CpG-DNA. The CD40 on NIPCs/PDCs de-
liver costimulatory signals when interacting with CD40-ligands, resulting
in IL-12 production and enhanced IFN-  synthesis in response to at least
CpG-DNA. The C-type lectin BDCA-2 is also depicted (natural ligand
unknown) and ligation of such molecules inhibits the IFN-  production.
The IFN-  finally acts on many cells, one immediate effect being costim-
ulation (priming) of NIPCs/PDCs that is essential for efficient IFN- 
production. Furthermore, the IFN-  acts on DCs and T- and B lympho-
cytes to counteract self-tolerance and promote autoimmunity. This results
in the immune-mediated inflammation seen in SLE, as well as generation
of more endogenous IFN-  inducers. 
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latory effects by these cytokines, but the genetic predisposi-
tion in a certain individual will eventually determine the
susceptibility to develop a specific autoimmune disease
during the prolonged type I IFN system activation. The
risk for such autoimmune reactions may be the price we
have to pay to be equipped with an efficient defense system
against microorganisms, especially viral infections. A great
challenge for the future is to learn more about the type I
IFN system in both health and disease and how this system
can be controlled and therapeutically modulated.
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